Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.
- Draft Medicare coverage expected to unlock US growth by 2027
- APAC commercial tests rise 12.9% with improved revenue and margins
- US sales strategy refocused on intermediate-risk microhematuria patients
- Clinical evidence program supports guideline inclusion and payer adoption
- Capital raising strengthens balance sheet amid revenue headwinds
Medicare Draft Coverage Sets Stage for US Recovery
Pacific Edge Limited (NZX:PEB) is navigating a critical inflection point as the US Medicare Administrative Contractor Novitas publishes a draft Local Coverage Determination (LCD) proposing reimbursement for its Cxbladder Triage and Triage Plus tests in intermediate-risk microhematuria patients. This draft, released in May 2026, marks the first time urine-based biomarkers for hematuria evaluation have been recognised as a Medicare benefit, creating a potential reimbursement pathway for over 66 million Medicare-insured lives.
The draft LCD’s exclusivity for Cxbladder tests establishes a protective moat around Pacific Edge’s microhematuria business. The company is actively engaging Novitas to expand coverage to high-risk microhematuria patients, citing new peer-reviewed evidence unavailable during the American Urological Association’s (AUA) 2025 guideline update. Pacific Edge’s CEO Dr Peter Meintjes emphasised the importance of this expanded inclusion, particularly for Medicare-aged men who may be unable to undergo cystoscopy due to comorbidities.
US Commercial Strategy Tightens Focus on Profitable Territories
Despite the Medicare uncertainty dampening US volumes, Pacific Edge’s commercial test numbers held broadly steady in Q1 2027, with a modest 2.4% decline to 3,295 tests amid a reduced sales force of five full-time equivalents (FTEs). The company’s sales efficiency metric improved substantially to 659 tests per sales FTE from 440 in the previous quarter, driven by increased adoption within Kaiser Permanente Southern California and a sharper focus on profitable territories.
Pacific Edge is recalibrating its US sales approach around the intermediate-risk microhematuria (IRMH) population, estimated at 1.14 million patients annually. This cohort is predominantly female and frequently treated outside traditional urology practices, including obstetrician-gynecologists and specialists in female pelvic medicine. The company is targeting Integrated Delivery Networks (IDNs) such as academic hospitals, Veterans Affairs medical centers, and hospital systems, where clinical pathways embedding Cxbladder tests can be implemented for more reliable reimbursement and longer-term revenue streams.
Asia Pacific Operations Near Profitability on Volume and Margin Growth
Pacific Edge’s Asia Pacific (APAC) business is showing clear signs of commercial momentum. APAC commercial tests rose 12.9% quarter-on-quarter in Q1 2027 to 1,158 tests, contributing 19% of operating revenue in H2 FY26, up from 8% in FY25. This growth is underpinned by disciplined cost management, improved pricing following a 2025 repricing program, and a shift towards the higher-margin Cxbladder Triage Plus test, which offers superior clinical performance.
Cash burn in APAC has fallen approximately 9% from the previous quarter to NZ$0.17 million and 15% year-on-year, with the region trending towards profitability on a direct cost basis. Early clinical pathway implementations in Singapore General Hospital and hospital contracting in Australia are laying the groundwork for broader adoption, while the company is building a network of laboratory and distribution partners across seven Asian markets.
Clinical Evidence Program Bolsters Market Position
Pacific Edge continues to invest in an extensive clinical evidence program designed to influence physician behaviour, payer policy, and guideline inclusion. The company’s studies adhere to rigorous frameworks of Analytical Validity, Clinical Validity, and Clinical Utility, with key publications supporting the inclusion of Cxbladder Triage in the AUA Microhematuria Guideline and underpinning the draft Medicare LCD’s coverage decisions.
Ongoing studies such as microDRIVE, AUSSIE, and pooled analyses are expected to publish in early 2027, potentially validating Cxbladder Triage Plus across all microhematuria risk categories. These results could support Pacific Edge’s push for broader Medicare coverage and expanded commercial payer adoption, including leveraging state biomarker laws that mandate reimbursement of Medicare-covered tests.
Capital Raising and Cost Management Support Strategic Reset
Pacific Edge closed a NZ$36.1 million capital raising in May 2026, comprising a NZ$25.4 million placement and a NZ$10.7 million retail offer. This funding bolsters the company’s balance sheet as it manages the revenue impact from Medicare non-coverage during FY26, which saw operating revenue fall 47% to NZ$11.5 million and a net loss widen to NZ$35.8 million.
Cost containment initiatives have reduced operating expenses by 9.5% year-on-year, including a 13.2% cut in sales and marketing spend. Monthly cash burn dropped 27.7% in the second half of FY26 compared to the first half. The company targets a further reduction to NZ$2.5 million monthly cash burn in FY27, down from NZ$2.85 million in FY26, reflecting prudent capital management ahead of Medicare coverage finalisation.
Pacific Edge’s strategic reset combines a focused US commercial model aligned with reimbursable use, ongoing clinical evidence generation, and a growing, near-profitable APAC business. The company is positioning itself to capitalise on the expected final Medicare LCD by early 2027, which could unlock substantial revenue growth and improve its path to profitability.
Bottom Line?
Pacific Edge’s Medicare draft coverage and APAC momentum set a foundation for growth, but final policy and commercial execution remain pivotal.
Questions in the middle?
- Will the final Medicare LCD expand coverage beyond intermediate-risk microhematuria?
- How quickly can Pacific Edge scale US commercial operations post-Medicare coverage?
- Can APAC sustain its trajectory toward profitability amid evolving market dynamics?